Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Angle PLC - Surrey, England-based medical diagnostics company - Says Prostate Cancer UK has given a £750,000 grant for a clinical study at Barts Cancer Institute, Queen Mary University of London. The trial will follow 200 men with localised prostate cancer over five years, assessed using Angle's Parsortix system, in bid to see whether the cancer will eventually spread.
Prostate cancer is the leading cause of cancer in men, with 1 in 8 men diagnosed in their lifetime.
‘We are pleased that Barts Cancer Institute is progressing investigation of clinical application of the Parsortix system in prostate cancer and, independent from the company, has secured substantial funding,’ says Founder & Chief Executive Andrew Newland.
‘Our aim is that the Parsortix system will be widely adopted by third parties seeking from their own initiative and funding to develop many and varied uses of the Parsortix system to support cancer patients.’
London stock price: 100.50 pence
12-month change: down 23%
Copyright 2022 Alliance News Limited. All Rights Reserved.